EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy

Husniye G Otlu, Tong Gao, Greg P Coffey, Jessica M Bright, Alyssa M A Toda, Pamela B Conley, Kazim Sheikh, Gang Zhang

Frontiers in Immunology · 27.05.2026 · 17

DOI: 10.3389/fimmu.2026.1857016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 27.05.2026. Verfasst von Husniye G Otlu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Housto…. Hauptthemen laut MEDLINE: Immunoglobulin G, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulin Fc Fragments, Guillain-Barre Syndrome. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated inflammatory neuropathies characterized by T cell– and/or autoantibody-driven injury to peripheral nerves. Although intravenous immunoglobulin (IVIg) is effective in both conditions, its use is limited by high dosing requirements, supply constraints, and manufacturing complexity. NVG-2089 is a recombinant IgG1 Fc-domain protein engineered to selectively agonize type II Fc receptors, promoting anti-inflammatory signaling through expansion of regulatory T cells (Tregs) and upregulation of the inhibitory Fcγ receptor FcγRIIB. Its efficacy in immune complex–mediated disease and T cell–driven neuroinflammation prompted evaluation of its therapeutic potential in an animal model of inflammatory demyelinating neuropathy.

Methods

We conducted a randomized, blinded preclinical study in the spontaneous autoimmune peripheral polyneuropathy model, a well-established murine model of inflammatory demyelinating neuropathy. Animals were treated with NVG-2089, high-dose IVIg, or vehicle. Outcomes included behavioral performance, nerve electrophysiology, peripheral nerve morphometrics, immunohistochemistry, and flow cytometric immunophenotyping.

Results

Both NVG-2089 and IVIg stabilized motor and sensory performance, preserved compound muscle action potential (CMAP) amplitudes, and attenuated demyelination-associated prolongation of distal latency and CMAP duration. Morphometric analyses demonstrated preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups. Immunophenotyping indicated an expansion of functionally activated CD25 + CD39 + Tregs in the spleen, along with increased FcγRIIB expression on B cells, monocytes, and dendritic cells across systemic and nerve-associated compartments, consistent with engagement of shared anti-inflammatory pathways.

Conclusions

NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose. These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunoglobulin Fc FragmentsGuillain-Barre SyndromeAnimalsMiceReceptors, IgGDisease Models, AnimalT-Lymphocytes, RegulatoryRecombinant ProteinsImmunoglobulins, IntravenousFemaleMale

Stichwörter der Autor:innen

FcγRIIBGuillain-Barré syndromeNVG-2089Tregchronic inflammatory demyelinating polyneuropathyintravenous immunoglobulintype II Fc receptors

Substanzen

Immunoglobulin GReceptors, IgGRecombinant ProteinsImmunoglobulins, IntravenousImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
  • Vocational Health Sciences, Laboratory Techniques Program, Malatya Turgut Ozal University, Malatya, Türkiye.
  • Nuvig Therapeutics, Menlo Park, CA, United States.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Otlu, H. G., Gao, T., Coffey, G. P., Bright, J. M., Toda, A. M. A., Conley, P. B., Sheikh, K., & Zhang, G. (2026). A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1857016

Vancouver

Otlu HG, Gao T, Coffey GP, Bright JM, Toda AMA, Conley PB, et al. A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1857016

BibTeX
@article{Otlu2026,
  author = {Otlu, Husniye G and Gao, Tong and Coffey, Greg P and Bright, Jessica M and Toda, Alyssa M A and Conley, Pamela B and Sheikh, Kazim and Zhang, Gang},
  title = {A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1857016}
}
Kostenlos starten →